嘌呤受体对血压的调节及研究进展

doi:10.3969/j.issn.1674-490X.2022.01.001

摘要/Abstract

摘要： 高血压是一种病因不明、并发症严重的多因素疾病。由于这种疾病的复杂性,大多数原发性高血压的发病机理仍然未知。嘌呤受体信号通路在多种疾病中起关键作用,构成一个无处不在的细胞间通讯系统,几乎所有嘌呤受体都在心血管系统的细胞上表达。根据现有的研究结果和推测,肯定了部分嘌呤受体亚型在血压调节中的作用,但了解的知识仍然有限。随着对嘌呤受体病理生理学认识日益加深,嘌呤受体化合物也正在被开发用于治疗高血压。现就嘌呤受体对血压的调节和最新的研究进展进行综述。

关键词: 嘌呤受体, 高血压, 心血管系统

Abstract: Hypertension is a multi-factor disease with unknown etiology and serious complications. Due to the complexity of this disease, the pathogenesis of most patients with essential hypertension is still unknown. A large body of evidence shows that the purinoceptor signaling pathway plays a key role in a variety of diseases and constitutes a ubiquitous intercellular communication system. Almost all purinoceptors are expressed on the cells of the cardiovascular system. Some purine receptor subtypes has been confirmed in blood pressure regulation according to the existing research results and conjectures, but the knowledge is still limited. With the increasing understanding of the pathophysiology of purinoceptors, purine receptor compounds are also being developed for the treatment of hypertension. Therefore, the article summarizes the effects of purinoceptors on blood pressure and the latest research developments.

Key words: purinoceptor, hypertension, cardiovascular system

中图分类号:

R544.1

王新新,李璐,武广义. 嘌呤受体对血压的调节及研究进展[J]. 医学研究与教育, 2022, 39(1): 1-7.

WANG Xinxin, LI Lu, WU Guangyi. Advances on the role of purine receptor in blood pressure regulation[J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(1): 1-7.

参考文献

[1] GBD 2016 Causes of Death Collaborators.Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet,2017,390:1151-1210.
[2] BURNSTOCK G. Purinergic signaling in the cardiovascular system[J].Circ Res,2017,120(1):207-228. DOI: 10.1161/CIRCRESAHA.116.309726.
[3] BURNSTOCK G. The therapeutic potential of purinergic signalling[J]. Biochem Pharmacol, 2018, 151(2): 157-165. DOI: 10.1016/j.bcp.2017.07.016.
[4] RALEVIC V. History of Geoff Burnstock's research on P2 receptors[J]. Biochem Pharmacol, 2021, 187: 114358. DOI: 10.1016/j.bcp.2020.114358.
[5] BURNSTOCK G, RALEVIC V. Purinergic signaling and blood vessels in health and disease[J]. Pharmacol Rev, 2013, 66(1): 102-192. DOI: 10.1124/pr.113.008029.
[6] BURNSTOCK G. Purine and purinergic receptors[J]. Brain Neurosci Adv, 2018, 2: 2398212818817494. DOI: 10.1177/2398212818817494.
[7] SZENTMIKLOSI A J, GALAJDA Z, CSEPPENTO A, et al. The Janus face of adenosine: antiarrhythmic and proarrhythmic actions[J]. Curr Pharm Des, 2015, 21(8): 965-976. DOI: 10.2174/1381612820666141029100346.
[8] VYAS F S, HARGREAVES A J, BONNER P L R, et al. A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: a role in cell survival[J]. Biochem Pharmacol, 2016, 107: 41-58. DOI: 10.1016/j.bcp.2016.03.016.
[9] DEB P K, DEKA S, BORAH P, et al. Medicinal chemistry and therapeutic potential of agonists, antagonists and allosteric modulators of A1 adenosine receptor: current status and perspectives[J]. Curr Pharm Des, 2019, 25(25): 2697-2715. DOI: 10.2174/1381612825666190716100509.
[10] LEE C B, KOH H C. Modification of the cardiovascular response of posterior hypothalamic adenosine A(2A)receptor stimulation by adenylate cyclase and KATP channel blockade in anesthetized rats[J]. Auton Neurosci, 2009, 146(1/2): 70-75. DOI: 10.1016/j.autneu.2008.11.015.
[11] BAHREYNI A, AVAN A, SHABANI M, et al. Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective[J]. J Cell Physiol, 2019, 234(2): 1295-1299. DOI: 10.1002/jcp.27161.
[12] KAUFFENSTEIN G, TAMAREILLE S, PRUNIER F, et al. Central role of P2Y6 UDP receptor in arteriolar myogenic tone[J]. Arterioscler Thromb Vasc Biol, 2016, 36(8): 1598-1606. DOI: 10.1161/ATVBAHA.116.307739.
[13] WANG S P, CHENNUPATI R, KAUR H, et al. Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release[J]. J Clin Invest, 2016, 126(12): 4527-4536. DOI: 10.1172/JCI87343.
[14] WANG S P, IRING A, STRILIC B, et al. P2Y2 and Gq/G11 control blood pressure by mediating endothelial mechanotransduction[J]. J Clin Invest, 2015, 125(8): 3077-3086. DOI: 10.1172/JCI81067.
[15] STRASSHEIM D, VERIN A, BATORI R, et al. P2Y purinergic receptors, endothelial dysfunction, and cardiovascular diseases[J]. Int J Mol Sci, 2020, 21(18): 6855. DOI: 10.3390/ijms21186855.
[16] BRAGANÇA B, CORREIA-DE-SÁ P. Resolving the ionotropic P2X4 receptor mystery points towards a new therapeutic target for cardiovascular diseases[J]. Int J Mol Sci, 2020, 21(14): 5005. DOI: 10.3390/ijms21145005.
[17] SATHANOORI R, ROSI F, GU B J, et al. Shear stress modulates endothelial KLF2 through activation of P2X4[J]. Purinergic Signal, 2015, 11(1): 139-153. DOI: 10.1007/s11302-014-9442-3.
[18] MENZIES R I, UNWIN R J, DASH R K, et al. Effect of P2X4 and P2X7 receptor antagonism on the pressure diuresis relationship in rats[J]. Front Physiol, 2013, 4: 305. DOI: 10.3389/fphys.2013.00305.
[19] CRAIGIE E, MENZIES R I, LARSEN C K, et al. The renal and blood pressure response to low sodium diet in P2X4 receptor knockout mice[J]. Physiol Rep, 2018, 6(20): e13899. DOI: 10.14814/phy2.13899.
[20] ZHOU J T, ZHOU Z C, LIU X J, et al. P2X7 receptor-mediated inflammation in cardiovascular disease[J]. Front Pharmacol, 2021, 12: 654425. DOI:10.3389/fphar.2021.654425.
[21] GONG C X, LIU X Z, DING L, et al. A non-synonymous polymorphism in purinergic P2X7 receptor gene confers reduced susceptibility to essential hypertension in Chinese postmenopausal women[J]. Clin Exp Hypertens, 2019, 41(6): 558-563. DOI: 10.1080/10641963.2018.1523914.
[22] ZHAO T V, LI Y, LIU X L, et al. ATP release drives heightened immune responses associated with hypertension[J]. Sci Immunol, 2019, 4(36): eaau6426. DOI: 10.1126/sciimmunol.aau6426.
[23] SHOKOPLES B G, PARADIS P, SCHIFFRIN E L. P2X7 receptors: an untapped target for the management of cardiovascular disease[J]. Arterioscler Thromb Vasc Biol, 2021,41(1): 186-199. DOI: 10.1161/atvbaha.120.315116.
[24] KRISHNAN S M, LING Y H, HUUSKES B M, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension[J]. Cardiovasc Res, 2019, 115(4): 776-787. DOI: 10.1093/cvr/cvy252.
[25] RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. DOI: 10.1056/NEJMoa1707914.
[26] ROTHMAN A M, MACFADYEN J, THUREN T, et al. Effects of interleukin-1β inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS[J]. Hypertension, 2020, 75(2): 477-482. DOI: 10.1161/HYPERTENSIONAHA.119.13642.
[27] NASCIMENTO M, PUNARO G R, SERRALHA R S, et al. Inhibition of the P2X7 receptor improves renal function via renin-angiotensin system and nitric oxide on diabetic nephropathy in rats[J]. Life Sci, 2020, 251: 117640. DOI: 10.1016/j.lfs.2020.117640.
[28] KOMALAVILAS P, LUO W F, GUTH C M, et al. Vascular surgical stretch injury leads to activation of P2X7 receptors and impaired endothelial function[J]. PLoS One, 2017, 12(11): e0188069. DOI: 10.1371/journal.pone.0188069.
[29] OLIVEIRA S D, COUTINHO-SILVA R, SILVA C L M. Endothelial P2X7 receptors' expression is reduced by schistosomiasis[J]. Purinergic Signal, 2013, 9(1): 81-89. DOI: 10.1007/s11302-012-9332-5.
[30] LIU C L,MATHER S,HUANG Y,et al.Extracellular ATP facilitates flow-induced vasodilatation in rat small mesenteric arteries[J].Am J Physiol Heart Circ Physiol,2004,286:H1688-H1695. DOI: 10.1152/ajpheart.00576.2003.
[31] CHIAO C W, DA SILVA-SANTOS J E, GIACHINI F R, et al. P2X7 receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction[J]. Clin Sci(Lond), 2013, 125(3): 131-141. DOI: 10.1042/CS20120479.
[32] BURNSTOCK G. Purinergic signalling: therapeutic developments[J]. Front Pharmacol, 2017, 8: 661. DOI: 10.3389/fphar.2017.00661.
[33] PIJACKA W, MORAES D J A, RATCLIFFE L E K, et al. Purinergic receptors in the carotid body as a new drug target for controlling hypertension[J]. Nat Med, 2016, 22(10): 1151-1159. DOI: 10.1038/nm.4173.
[34] HO M F, LOW L M, ROSE'MEYER R B. Pharmacology of the adenosine A3 receptor in the vasculature and essential hypertension[J]. PLoS One, 2016, 11(2): e0150021. DOI: 10.1371/journal.pone.0150021.